Use of human epididymis protein 4 (HE4) for assessing responsiveness of MUC 16-positive cancer treatment
US11440969B2 · kind B2 · utility
1Cited by
20References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 4, 2019 |
| Grant date | Sep 13, 2022 |
| Priority date | — |
| Expiry date | Mar 7, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods and kits or articles of manufacture related thereto that may find use, inter alia, in assessing responsiveness of cancers to MUC16 antagonists by monitoring HE4 expression. In some embodiments, the methods include measuring the level of expression of HE4 in a sample from a subject; comparing the level of expression of HE4 in the sample with the level of expression of HE4 in a sample previously obtained from the subject; and, optionally, administering to the subject a therapeutically effective amount of a MUC16 antagonist.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.